News of Note—Curevo, Merck, Inovio and more

In this week's news of note, Merck's experimental Ebola vaccine has been deployed in Congo. (Pixabay)

In conjunction with the Infectious Disease Research Institute and Mogam Institute for Biomedical Research, South Korea's GC Pharma formed a new company in Seattle dubbed Curevo to conduct vaccine R&D. Release

A new study from the American Society for Microbiology and Research America found that the U.S. public's confidence in vaccines has slipped from 2008. U.S. News & World Report story

Inovio Pharmaceuticals started a phase 2 study of its cancer vaccine VGX-3100 in patients with HPV-related anal dysplasia. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Merck's experimental Ebola vaccine has been deployed against an outbreak in the Democratic Republic of Congo. Reuters story

FluGen kicked off a study testing its universal flu vaccine candidate's ability to protect against a flu strain mismatched by 6 years. Release

In an interim analysis of a phase 2 trial, MimiVax said its SurVaxM provided a significant survival benefit in newly diagnosed glioblastoma patients over historical standard of care. Release

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.